Medtronic PLC Earnings - Q1 2027 Analysis & Highlights
Medtronic reported strong Q1 FY2027 results driven by broad-based growth across multiple business segments, strategic investments in high-growth markets, and confidence in achieving elevated full-year guidance, with management emphasizing execution discipline and capital allocation focused on innovation and inorganic opportunities in attractive markets.
Key Financial Results
Q1 FY2027 revenue reached $9.8 billion with organic growth of 13.7%, well ahead of expectations, though this included approximately $570 million or 670 basis points from an extra selling week in the 53-week fiscal year.
Adjusted EPS was $1.45, $0.06 above the midpoint of guidance range and Street expectations.
Adjusted gross margin was 65.2%, up 10 basis points year-over-year, driven by 30 basis points of pricing benefit and 50 basis points from cost-down initiatives, partially offset by 50 basis points of unfavorable mix.
Adjusted operating profit increased 15% year-over-year to $2.3 billion, resulting in an adjusted operating margin of 23.7%, up 10 basis points from the prior year.
Free cash flow performance was very strong in Q1 with cash conversion at 70%, with management indicating a strong path to reaching 80%.
The company rationalized more than 9,000 SKUs in Q1, streamlining the product portfolio to focus on areas with greatest customer impact while enhancing supply chain performance.
Business Segment Results
Cardiac Rhythm Management delivered outstanding global growth of 15%, with balanced performance between US and international markets, gaining 80 basis points of global share, driven by strength in high-power and low-power therapies including EV-ICD, Micra, and conduction system pacing.
Cranial & Spinal Technologies delivered 13% global growth, including 14% in the US and 10% internationally, with the AiBLE ecosystem and recently launched Stealth AXiS platform meaningfully outperforming, while US spine robotics penetration remains in single digits.
Surgical delivered 9% global growth as the largest operating unit with over $6 billion in annual revenue, with strength in advanced energy and wound management driven by LigaSure vessel sealing and V-Loc barred sutures, plus increased contribution from Hugo robotics.
Cardiac Ablation Solutions delivered 88% worldwide growth, with Sphere-9 momentum continuing with a 9-point increase in US share during the quarter, surpassing the $2 billion mark in trailing 12-month revenue.
Electrophysiology Therapies grew 29% including 41% in the US and 18% internationally, with Cardiac Ablation Solutions delivering 88% growth, up 139% in the US.
Interventional Cardiology Therapies grew 7% globally, driven mainly by 11% international growth, with Structural Heart growing low-single digits and Coronary & Renal Denervation growing 13% globally.
Cardiovascular Surgery grew 8% globally and Peripheral Vascular Health was up 11%.
Neuroscience portfolio grew 9% worldwide, driven by 11% in the US and 7% internationally, with Cranial & Spinal Technologies delivering 13% growth and Specialty Therapies up 7%.
Pelvic Health delivered 15% growth globally, with Altaviva procedures doubling sequentially and Medtronic continuing to outpace peers in Sacral Neuromodulation.
Medical Surgical delivered 10% growth globally with balanced performance in the US and internationally, while Acute Care & Monitoring was up 14% globally including high teens growth in the US.
Diabetes business delivered 15% growth, driven by US acceleration and robust growth internationally.
Geographically, the US saw nearly 16% growth and international markets saw 12% growth.
Capital Allocation
Medtronic announced a strategic investment and distribution agreement for Cornerstone Robotics' Sentire Surgical System in select markets outside the US, representing a $700 million investment with foregone interest embedded in guidance.
The company made a strategic investment in Pi-Cardia, the first FDA-cleared leaflet modification technology for TAVR procedures for patients at risk for coronary obstruction.
Recent acquisitions including SPR Therapeutics and Scientia are expected to contribute over $150 million to inorganic growth in fiscal year 2027, with both operating in markets with CAGRs exceeding 20%.
Over the last 12 months, the company increased R&D and acquisitions from approximately $2.8 billion in R&D and $0.5 billion in acquisitions to almost $3 billion in R&D and $2 billion in acquisitions or investments, more than doubling investment in innovation.
No specific plans for share buybacks were announced, though management indicated willingness to execute buybacks for tactical reasons if conditions are right.
The company maintains a strong balance sheet and free cash flow generation, providing significant firepower for capital deployment.
Industry Trends and Dynamics
Robotic-assisted surgery is one of the most compelling growth opportunities in healthcare, with global penetration still in single digits and only 1% in emerging markets, with procedure volumes up approximately 16% per year over the last decade.
The broader EP space remains healthy, growing in the mid-teens, with Medtronic expecting Cardiac Ablation Solutions to grow at more than 2.5 times the market rate this fiscal year.
Q1 was characterized by healthy underlying procedure volumes across nearly all end markets and geographies, with strength broad-based and not concentrated in any one therapy or region.
Resilient demand continues across chronic disease, high acuity conditions and life-saving interventions, areas where Medtronic is particularly well positioned given differentiated innovation and strong clinical evidence.
The underlying demand backdrop remains constructive, reinforcing confidence in the durability of growth.
Competitive Landscape
Medtronic is gaining share rapidly in Cardiac Ablation Solutions, picking up 9 points of share in one of the highest growth segments in MedTech.
In Cardiac Rhythm Management, the company gained 80 basis points of global share while maintaining balanced performance between US and international markets.
Medtronic continues to outpace peers in Sacral Neuromodulation, with Altaviva's performance now more than offsetting SNM market softness.
The company believes there will be two or three platforms that will win in the robotic surgery market, and is building out a portfolio of offerings to meet customer needs and specifics of their situation.
Management expressed confidence in Medtronic's position in soft tissue robotics, stating the company wants to become a meaningful number two and gain on the market leader with a multiyear head start over the next scaled competitor.
Sphere-9 remains one of a kind in the dual-energy point-to-point ablation space with many different features and benefits that physicians like.
Macroeconomic Environment
Foreign exchange is expected to be a roughly $50 million to $150 million headwind for the full year, with approximate $25 million to $75 million headwinds in Q2 based on recent FX rates.
Tariff-related impact was a slight headwind in Q1 as tariffs paid were largely offset by related refunds, with the company not embedding future refunds in guidance and remaining prudent going forward.
Management continues to monitor the broader environment closely, though the underlying demand backdrop remains constructive.
Growth Opportunities and Strategies
Cardiac Ablation Solutions is building out a comprehensive EP platform spanning mapping, ice catheters, focal ablation software, and single shot innovation, positioning the company to serve electrophysiologists with more complete solutions.
Sphere-9 achieved CE Mark for treatment of ventricular arrhythmias including ventricular tachycardia, opening the door to a patient population that is notoriously difficult to treat, with US VT pivotal trial enrollment underway.
Symplicity real-world outcomes continue to improve, with the SPYRAL AFFIRM clinical trial accepted as a late-breaker at TCT, and the transradial catheter remaining on track to launch in the second half of fiscal year.
Altaviva procedures doubled sequentially in Q1, with demand building as the company expands training, reimbursement support and patient awareness.
Hugo is expected to surpass 50,000 completed procedures by end of fiscal year, with procedure growth continuing at more than twice the market rate, and new capabilities and indications including expected US expansions into general surgery and gynecology.
Medtronic is building a connected surgical ecosystem integrating robotics, advanced visualization, navigation, instrumentation and digital technologies, including AI-enabled capabilities like Touch Surgery used in more than 1,500 operating rooms globally.
Touch Surgery Aide was unveiled with 300 times more computing power in the operating room, creating a foundation for increasingly advanced AI capabilities over time.
The Cornerstone Robotics investment extends Medtronic's reach into select international markets and broadens the range of customer needs that can be addressed as robotic surgery continues to expand globally.
Medtronic is making targeted investments in Structural Heart including the Anteris investment in the TAVR space, heavy investment in tricuspid and mitral replacement, and ecosystem building with DASI on sizing.
Renal Denervation is being driven by improving clinical evidence, broader reimbursement coverage, and market development, with real-world outcomes showing over 18-point reduction in office blood pressure and over 13-point reduction in ambulatory setting.
Medtronic is pursuing multiple shots on goal in high-growth areas, combining organic programs with inorganic investments to build winning strategies.
The company is prioritizing capital allocation to the highest growth opportunities in MedTech with large patient pools where Medtronic has a right to win, with strong commercial presence, good reputation, and understanding of clinical nature and technologies.
Financial Guidance and Outlook
Fiscal year 2027 organic revenue growth guidance was raised to 7.25% to 7.75%, representing a 50 basis points increase from prior guidance.
Q2 organic revenue growth is expected to be roughly 6%.
Fiscal year 2027 operating profit is expected to grow approximately 10%, with operating margin expanding approximately 50 basis points year-over-year.
Fiscal year 2027 EPS guidance range was raised to $5.94 to $6.00.
Q2 EPS is expected in the range of $1.32 to $1.34, which includes a roughly neutral impact from foreign exchange at recent rates.
Pricing and COGS efficiency programs are expected to continue offsetting the impact of business mix, which is primarily from Diabetes and Cardiac Ablation Solutions.
The gross margin headwind from business mix is expected to reduce following completion of the MiniMed separation, which the company intends to close prior to fiscal year-end.
In Q2, Cardiac Ablation Solutions is expected to outpace the market by more than 3x, with growth rates moderating over the remainder of the fiscal year as the company laps increasingly strong comps.
Acute Care & Monitoring is expected to normalize as the company moves through 2027 after strong mid-40s growth in McGRATH video laryngoscopy and high-30s in Microstream capnography in Q1.
Pelvic Health is expected to become a stronger and stronger contributor to Neuroscience in fiscal year 2027 and beyond.
Neurovascular is expected to accelerate to mid-single digit growth in the back half of the year, partly from the acquisition of Scientia.
The company will host an Investor Day on December 10 and 11 to share deeper insights on portfolio, pipeline, capital allocation strategy, and long-term growth opportunities.
Product Portfolio and Innovation
Medtronic's three largest businesses—Cardiac Rhythm Management, Cranial & Spinal Technologies, and Surgical—all delivered strong results in Q1.
Micra, which launched more than a decade ago, continues to grow at a healthy double-digit rate, underscoring the lasting impact of meaningful innovation within Cardiac Rhythm Management.
Conduction system pacing continues to gain momentum, adding over 200 basis points to Cardiac Rhythm Management in the first quarter.
Onyx 12 received US FDA approval for MMA embolization to treat subdural hematomas, with all three Onyx viscosities now approved for a one-minute shake time versus the conventional 20 minutes.
The acquisition of Scientia represents an important advancement in navigation, enabling neurointerventionalists to reach areas of the brain that have historically been extremely difficult to access.
Endoflip 300 system and PillCam drove high-single digit growth in Endoscopy.
McGRATH video laryngoscopy grew mid-40s, Microstream capnography grew high-30s, and Nellcor pulse oximetry grew high-single digits in Acute Care & Monitoring.
Diabetes Business and Separation
The Diabetes business delivered 15% growth, driven by US acceleration and robust growth internationally.
Strategic intent for the separation of MiniMed remains unchanged, with the goal of creating two focused companies that will allow both MiniMed and Medtronic to execute more effectively and pursue distinct capital allocation strategies.
The Diabetes business is fundamentally different from the rest of Medtronic, being more consumer-based and materially lower-margin than the rest of the company.
Separation of Diabetes will result in approximately 20 basis points of growth loss for Medtronic, but will increase gross margin by about 50 basis points and operating margin by about 100 basis points.
Every single Diabetes launch is happening ahead of schedule, providing favorable innovation momentum.
